Medline Faces Shareholder Probe Over Hidden Manufacturing Lapses
A $2.2 billion collapse in market capitalization has triggered a formal investigation into Medline Inc. by Hagens Berman Sobol Shapiro. The firm is examining whether the medical supply company misled investors by concealing systemic failures in quality control and repeated instances of microbial contamination at its manufacturing facilities.
Since its December 2025 public offering, Medline had maintained a narrative of rigorous quality assurance, touting a dedicated team of 2,400 employees to ensure safety standards. That narrative unraveled on June 2, 2026, when the FDA released a warning letter sent to CEO Boyle. The regulatory document revealed that the company had isolated objectionable microorganisms from finished drug products on nine separate occasions between June 2023 and August 2025.
Investigations further show that Medline failed to address these contamination risks despite previous warnings in January 2025. The company only disclosed that it had shuttered specific facilities last October after the FDA's public rebuke. Reed Kathrein, the partner leading the HBSS investigation, is now focusing on the timeline of these disclosures to determine if leadership knowingly withheld critical safety data from shareholders. The firm is currently seeking input from investors and potential whistleblowers who may hold further evidence regarding the company's internal compliance failures.
Comments (0)
No comments yet. Be the first!